These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 27163502

  • 1. Pharmacokinetics, Safety, and Tolerability of Once-Daily Intranasal Fluticasone Furoate and Levocabastine Administered Alone or Simultaneously as fluticasone Furoate/Levocabastine Fixed-Dose Combination.
    Allen A, Murdoch RD, Bareille P, Burns O, Hughes S, Gupta A, Miller SR.
    Clin Pharmacol Drug Dev; 2016 May; 5(3):225-31. PubMed ID: 27163502
    [Abstract] [Full Text] [Related]

  • 2. The improved efficacy of a fixed-dose combination of fluticasone furoate and levocabastine relative to the individual components in the treatment of allergic rhinitis.
    Murdoch RD, Bareille P, Ignar D, Miller SR, Gupta A, Boardley R, Zieglmayer P, Zieglmayer R, Lemel P, Horak F.
    Clin Exp Allergy; 2015 Aug; 45(8):1346-55. PubMed ID: 25900517
    [Abstract] [Full Text] [Related]

  • 3. The pharmacodynamics, pharmacokinetics, safety and tolerability of inhaled fluticasone furoate and vilanterol administered alone or simultaneously as fluticasone furoate/vilanterol.
    Kempsford R, Allen A, Bareille P, Hamilton M, Cheesbrough A.
    Clin Pharmacol Drug Dev; 2015 Jan; 4(1):2-11. PubMed ID: 27127998
    [Abstract] [Full Text] [Related]

  • 4. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 5. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
    Allen A, Down G, Newland A, Reynard K, Rousell V, Salmon E, Scott R.
    Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
    Medley H, Orozco S, Allen A.
    Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
    [Abstract] [Full Text] [Related]

  • 7. Once-daily dosing of levocabastine has comparable efficacy to twice-daily dosing in the treatment of allergic rhinitis assessed in an allergen challenge chamber.
    Murdoch RD, Bareille P, Ignar D, Mark S, Miller SR, Gupta A, Salapatek AM, Patel P.
    Int J Clin Pharmacol Ther; 2015 Oct; 53(10):811-8. PubMed ID: 26249767
    [Abstract] [Full Text] [Related]

  • 8. Open-Label, Randomized, 6-Way Crossover, Single-Dose Study to Determine the Pharmacokinetics of Batefenterol (GSK961081) and Fluticasone Furoate When Administered Alone or in Combination.
    Ambery C, Riddell K, Daley-Yates P.
    Clin Pharmacol Drug Dev; 2016 Sep; 5(5):399-407. PubMed ID: 27170445
    [Abstract] [Full Text] [Related]

  • 9. The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects.
    Nakahara N, Wakamatsu A, Kempsford R, Allen A, Yamada M, Nohda S, Hirama T.
    Int J Clin Pharmacol Ther; 2013 Aug; 51(8):660-71. PubMed ID: 23735179
    [Abstract] [Full Text] [Related]

  • 10. Open-Label, Crossover Study to Determine the Pharmacokinetics of Fluticasone Furoate and Batefenterol When Administered Alone, in Combination, or Concurrently.
    Ambery C, Young G, Fuller T, Georgiou A, Ramsay D, Puri A, Daley-Yates P.
    Clin Pharmacol Drug Dev; 2019 Feb; 8(2):188-197. PubMed ID: 30070770
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers.
    Brealey N, Gupta A, Renaux J, Mehta R, Allen A, Henderson A.
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):753-64. PubMed ID: 26227101
    [Abstract] [Full Text] [Related]

  • 12. A randomized, crossover study to investigate the pharmacokinetics and safety of inhaled fluticasone furoate and umeclidinium, administered separately and in combination via dry powder inhaler in healthy adult volunteers.
    Yang S, Lee L, Mallett S, Ayer J, Wolstenholme A, Pascoe S.
    Adv Ther; 2015 Feb; 32(2):157-71. PubMed ID: 25700806
    [Abstract] [Full Text] [Related]

  • 13. The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study.
    Lee LA, Yang S, Kerwin E, Trivedi R, Edwards LD, Pascoe S.
    Respir Med; 2015 Jan; 109(1):54-62. PubMed ID: 25452139
    [Abstract] [Full Text] [Related]

  • 14. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination.
    Allen A, Davis A, Hardes K, Tombs L, Kempsford R.
    Clin Ther; 2012 Dec; 34(12):2316-32. PubMed ID: 23200625
    [Abstract] [Full Text] [Related]

  • 15. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis.
    Rosenblut A, Bardin PG, Muller B, Faris MA, Wu WW, Caldwell MF, Fokkens WJ.
    Allergy; 2007 Sep; 62(9):1071-7. PubMed ID: 17686110
    [Abstract] [Full Text] [Related]

  • 16. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate.
    Allen A, Bareille PJ, Rousell VM.
    Clin Pharmacokinet; 2013 Jan; 52(1):37-42. PubMed ID: 23184737
    [Abstract] [Full Text] [Related]

  • 17. The Pharmacokinetics of Fluticasone Furoate Given Intranasally in Healthy Subjects Using an Ultra-Sensitive Analytical Assay.
    Bouhajib M, Tayab Z.
    Drug Res (Stuttg); 2020 Jul; 70(7):310-316. PubMed ID: 32485781
    [Abstract] [Full Text] [Related]

  • 18. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial.
    Bateman ED, Bleecker ER, Lötvall J, Woodcock A, Forth R, Medley H, Davis AM, Jacques L, Haumann B, Busse WW.
    Respir Med; 2012 May; 106(5):642-50. PubMed ID: 22342538
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT, Feldman G, Korenblat P, LaForce CF, Locantore N, Pistolesi M, Watkins ML, Crim C, Martinez FJ.
    Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects.
    Allen A, Bal J, Cheesbrough A, Hamilton M, Kempsford R.
    Br J Clin Pharmacol; 2014 May; 77(5):808-20. PubMed ID: 24152086
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.